Financial profit lifts Richter earnings in Q1
Hungarian drugmaker Richter's first-quarter net income climbed 13.7% to HUF 19.1 billion from the same period a year earlier, lifted by financial profit, the company's consolidated IFRS report for the period published early Thursday shows. Richter's revenue rose and direct cost of sales fell during the period, but operating profit edged down because of higher spending on sales and marketing and research and development. Financial profit of HUF 4.7 billion – a little more than double that in the base period – lifted the bottom line. Net income was over the HUF 16.2 billion estimate by analysts polled by Portfolio.hu. Diluted earnings per share came to HUF 1,022. Revenue rose 4.7% to HUF 85.8 billion. Cost of sales fell 1.8% to HUF 30.9 billion, raising gross profit by 8.7% to HUF 54.9 billion. Sales and marketing costs increased 20.1% to HUF 26.8 billion on the expansion of Richter's women's healthcare sales network in Western Europe, promotional spending for the launch of a new drug for uterine fibroids, Esmya, and the activities of the company's joint venture in China. R&D spending was up 14.1% at HUF 11.0 billion. CAPEX rose 16.9% to HUF 3.2 billion.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.